Fulcrum Therapeutics, Inc. Forecasted to Post Q2 2022 Earnings of ($0.63) Per Share (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULCGet Rating) – Oppenheimer raised their Q2 2022 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research report issued to clients and investors on Monday, May 9th. Oppenheimer analyst M. Biegler now anticipates that the company will earn ($0.63) per share for the quarter, up from their prior forecast of ($0.65). Oppenheimer has a “Outperform” rating and a $33.00 price objective on the stock. Oppenheimer also issued estimates for Fulcrum Therapeutics’ Q3 2022 earnings at ($0.66) EPS, Q4 2022 earnings at ($0.69) EPS, FY2022 earnings at ($2.61) EPS, FY2023 earnings at ($2.36) EPS, FY2024 earnings at ($2.58) EPS, FY2025 earnings at ($2.28) EPS and FY2026 earnings at ($1.59) EPS.

Fulcrum Therapeutics (NASDAQ:FULCGet Rating) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.07. Fulcrum Therapeutics had a negative return on equity of 48.38% and a negative net margin of 529.15%. The firm had revenue of $5.06 million during the quarter, compared to analyst estimates of $4.00 million. During the same quarter in the prior year, the business posted ($0.64) EPS.

Several other equities analysts also recently issued reports on FULC. Piper Sandler cut their target price on Fulcrum Therapeutics from $46.00 to $42.00 in a research report on Thursday, March 3rd. HC Wainwright assumed coverage on Fulcrum Therapeutics in a research report on Friday, March 4th. They issued a “buy” rating and a $40.00 target price on the stock. Zacks Investment Research downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America raised Fulcrum Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Thursday, March 3rd. Finally, Morgan Stanley upped their target price on Fulcrum Therapeutics from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.72.

NASDAQ FULC opened at $8.28 on Thursday. The stock’s fifty day moving average price is $15.14 and its 200 day moving average price is $15.06. Fulcrum Therapeutics has a 1 year low of $6.85 and a 1 year high of $33.10. The company has a market cap of $338.22 million, a price-to-earnings ratio of -3.46 and a beta of 2.52.

Large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at about $47,000. Denali Advisors LLC purchased a new position in Fulcrum Therapeutics in the 4th quarter valued at about $69,000. Royal Bank of Canada lifted its stake in Fulcrum Therapeutics by 113.4% in the 3rd quarter. Royal Bank of Canada now owns 3,240 shares of the company’s stock valued at $91,000 after buying an additional 1,722 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Fulcrum Therapeutics in the 4th quarter valued at about $103,000. Finally, Bank of America Corp DE lifted its stake in Fulcrum Therapeutics by 105.3% in the 2nd quarter. Bank of America Corp DE now owns 10,277 shares of the company’s stock valued at $108,000 after buying an additional 5,272 shares in the last quarter. Hedge funds and other institutional investors own 97.15% of the company’s stock.

In other news, Director Robert J. Gould sold 34,464 shares of the firm’s stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $24.03, for a total transaction of $828,169.92. Following the sale, the director now directly owns 506,630 shares in the company, valued at approximately $12,174,318.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert J. Gould sold 5,631 shares of the firm’s stock in a transaction dated Thursday, April 7th. The shares were sold at an average price of $24.02, for a total value of $135,256.62. Following the sale, the director now owns 506,630 shares in the company, valued at $12,169,252.60. The disclosure for this sale can be found here. Insiders have sold a total of 47,330 shares of company stock worth $1,137,211 over the last 90 days. Insiders own 22.30% of the company’s stock.

About Fulcrum Therapeutics (Get Rating)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Featured Stories

Earnings History and Estimates for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.